Tumor and blood B-cell abundance outperforms established immune checkpoint blockade response prediction signatures in head and neck cancer
- 17 November 2024
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 36 (3) , 309-320
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Cancer Institute (1ZIABC011803-01)
This publication has 56 references indexed in Scilit:
- Does ‘B’ stand for ‘benefit’? Decoding the B-cell neighborhood in head and neck cancer for predicting therapeutic response to PD-1 inhibitorsAnnals of Oncology, 2024
- B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinomaAnnals of Oncology, 2023
- Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomesCancer Cell, 2022
- Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapyCell, 2022
- High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer typesAnnals of Oncology, 2021
- Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: A systematic review and meta-analysisCritical Reviews in Oncology/Hematology, 2020
- The effects and safety of PD‐1/PD‐L1 inhibitors on head and neck cancer: A systematic review and meta‐analysisCancer Medicine, 2019
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methodsInternational Journal of Cancer, 2018
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic ActivityCell, 2015
- B Cells Regulate Macrophage Phenotype and Response to Chemotherapy in Squamous CarcinomasCancer Cell, 2014